Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended January 31, 1997, for CopyTele, Inc. (Note: The request metadata listed "Anixa Biosciences Inc," but the filing text explicitly identifies the registrant as CopyTele, Inc.). The company is classified as a Development Stage Enterprise incorporated in November 1982. Its principal activities involve developing telephone-based multi-functional telecommunications products (specifically the MAGICOM(R) 2000) utilizing flat panel display technology and managing a 55% owned joint venture in Shanghai, China (Shanghai CopyTele Electronics Co., Ltd. or "SCE").
Key Financial Metrics
| Metric | Three Months Ended Jan 31, 1997 | Three Months Ended Jan 31, 1996 | Inception through Jan 31, 1997 |
|---|---|---|---|
| Revenue (Sales) | $0 | $0 | $0 |
| Net Loss | ($1,370,445) | ($971,319) | ($30,128,825) |
| Net Loss Per Share | ($0.02) | ($0.02) | ($0.67) |
| Operating Expenses (SG&A) | $1,562,504 | $1,075,396 | $33,542,713 |
| Research & Development (included in SG&A) | $898,000 | $767,000 | $21,641,000 |
| Interest Income | $261,076 | $116,949 | $3,649,348 |
| Cash and Cash Equivalents (Ending) | $19,546,294 | $10,177,938 | $19,546,294 |
| Net Cash Used in Operating Activities | ($2,624,240) | ($749,616) | ($29,393,006) |
| Current Liabilities | $1,472,407 | $1,960,147 | N/A |
| Accumulated Deficit | ($30,128,825) | ($28,758,380) | ($30,128,825) |
Material Changes vs. Prior Period
- Increased Operating Loss: The net loss for the quarter increased by approximately $399,000 compared to the same period in 1996, driven primarily by higher selling, general, and administrative expenses.
- Expense Growth: SG&A expenses rose by approximately $488,000. This increase is attributed to higher marketing expenses (opening a marketing office, hiring PR/advertising firms) and increased compensation, rent, and travel costs due to expanded personnel in marketing and engineering.
- Joint Venture Loss: The company's share of the loss from its Chinese joint venture (SCE) increased from approximately $13,000 in the prior year quarter to $69,000, reflecting SCE's commencement of initial production stages for the MAGICOM(R) 2000.
- Interest Income: Interest income increased by $144,000 due to higher funds available for investment (weighted average of ~$20.2M vs. ~$9.4M) and slightly higher interest rates.
- Cash Position: Cash and cash equivalents decreased by approximately $2.6 million during the quarter, primarily due to operating cash outflows and capital expenditures for property and equipment.
Guidance, Outlook, and Risks
- Revenue Outlook: The company has generated no revenue since inception. There is no assurance that it will generate significant revenues in the future or that products will not be rendered obsolete by competitors.
- Liquidity and Capital Resources: Management believes it has sufficient funds through the first quarter of fiscal 2000 to maintain current development efforts and make anticipated capital contributions to joint ventures, assuming continued salary waivers by senior executives. However, additional funding may be required for future joint venture participation and R&D.
- Joint Venture Capital Needs: The primary joint venture (SCE) may require up to $25 million in capitalization. A second joint venture is in discussion with an initial capitalization of approximately $2 million, potentially requiring up to $10 million ultimately.
- Listing Requirements: The company must maintain a minimum of $4,000,000 in net tangible assets to maintain its NASDAQ-NMS listing. It anticipates seeking additional funding if necessary to meet this requirement.
- Stock-Based Compensation: The company accounts for stock options using the intrinsic value method (APB 25). If it had adopted SFAS No. 123, the pro forma net loss for the quarter would have been approximately $4.35 million (vs. reported $1.37 million).
Investor Verification Checklist
- Company Identity: Verify that the filing pertains to CopyTele, Inc., not Anixa Biosciences Inc.
- Revenue Generation: Confirm the company remains in the development stage with zero sales revenue to date.
- Cash Burn Rate: Review the quarterly cash burn of ~$2.6 million against the $19.5 million cash balance to assess runway duration.
- Executive Compensation Waivers: Note that the liquidity projection relies on the Chairman, President, and senior personnel continuing to waive salaries and pension benefits.
- Joint Venture Exposure: Assess the risk associated with the 55% owned Chinese joint venture, which is currently operating at a loss and may require significant additional capital.
- Pro Forma Loss: Consider the potential impact of SFAS No. 123 on reported earnings, which could triple the reported quarterly loss.